| Recruiting | Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (IT NCT07362199 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) NCT07362238 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Not Yet Recruiting | A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases NCT07212322 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombo NCT07234019 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) NCT07297563 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Not Yet Recruiting | The Value of Interleukin-1β and Interleukin-33 Genetic Expression in the Pathogenesis and Differentiation of P NCT07298733 | Sohag University | — |
| Recruiting | Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood NCT07104565 | Incyte Corporation | Phase 2 |
| Not Yet Recruiting | Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia NCT07315373 | Peking University People's Hospital | Phase 1 |
| Recruiting | Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia NCT07206758 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 |
| Recruiting | Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) W NCT07007962 | Sanofi | Phase 3 |
| Active Not Recruiting | Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan NCT07216079 | Sanofi | Phase 3 |
| Recruiting | Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) NCT07063199 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Not Yet Recruiting | The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocyt NCT07064889 | Peking University People's Hospital | Phase 2 |
| Recruiting | A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia NCT06776510 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia NCT06715215 | Sohag University | N/A |
| Recruiting | Longitudinal Cohort of Thrombosis and Hemostasis Diseases NCT06727669 | Peking University People's Hospital | — |
| Recruiting | Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia NCT06817395 | Massachusetts General Hospital | — |
| Recruiting | Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP) NCT06519565 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | EARLY_Phase 1 |
| Completed | Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets a NCT06444477 | University Hospital, Bordeaux | — |
| Recruiting | Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) NCT06838962 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatmen NCT06478537 | Peking Union Medical College Hospital | Phase 2 |
| Not Yet Recruiting | Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases NCT06417398 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | EARLY_Phase 1 |
| Completed | Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP) NCT06287567 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Withdrawn | The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune NCT06291415 | Hutchmed | Phase 1 |
| Recruiting | Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia NCT06281327 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Active Not Recruiting | A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of I NCT06199089 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP) NCT06168851 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Withdrawn | Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocy NCT06176235 | Peking University People's Hospital | Phase 2 |
| Unknown | The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia NCT06176911 | Peking University People's Hospital | Phase 2 |
| Unknown | Teriflunomide for Steroid-resistant/Relapse Immune Thrombocytopenia NCT06190145 | Peking University People's Hospital | Phase 2 |
| Unknown | Use of Vitamin D as An Adjuvant Treatment in Children With Chronic Idiopathic Thrombocytopenic Purpura NCT06073925 | Mansoura University | EARLY_Phase 1 |
| Recruiting | A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Th NCT06094881 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Biologic Characterization of Patients With ITP NCT05694325 | Gruppo Italiano Malattie EMatologiche dell'Adulto | N/A |
| Recruiting | Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy NCT06577909 | Peking University People's Hospital | Phase 2 |
| Recruiting | A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia NCT05995054 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Unknown | Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia NCT05932524 | Peking University People's Hospital | Phase 2 |
| Active Not Recruiting | An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias NCT05757570 | Alpine Immune Sciences, Inc. | Phase 1 / Phase 2 |
| Unknown | CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus NCT05930314 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Unknown | Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia NCT05852847 | Peking University People's Hospital | Phase 2 |
| Unknown | Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia NCT05685420 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia NCT05694767 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Unknown | Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies NCT05654766 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | — |
| Unknown | IVIg Plus Low Dose rhTPO for ITP in Pregnancy NCT05634824 | Peking University People's Hospital | Phase 2 |
| Active Not Recruiting | A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytope NCT05562882 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Short-course High-dose Prednisone and Dexamethasone in Children With ITP NCT05522465 | Fujian Medical University Union Hospital | Phase 4 |
| Unknown | The Expression of Immune Checkpoint CD28 rs1980422-related Single-nucleotide Polymorphisms in the Primary Immu NCT05468866 | Sohag University | N/A |
| Unknown | The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombo NCT05494307 | Peking University People's Hospital | Phase 2 |
| Unknown | Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluati NCT04735588 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Unknown | Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia NCT05459649 | Peking University People's Hospital | Phase 2 |
| Unknown | Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia NCT05446831 | Peking University People's Hospital | Phase 2 |
| Completed | Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP NCT05369208 | Sobi, Inc. | Phase 3 |
| Unknown | Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia NCT05369377 | Peking University People's Hospital | Phase 2 |
| Not Yet Recruiting | The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocyt NCT05369364 | Peking University People's Hospital | Phase 2 |
| Unknown | Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia NCT05302024 | Peking University People's Hospital | Phase 2 |
| Unknown | The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopeni NCT05471050 | Peking University People's Hospital | Phase 2 |
| Completed | An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP NCT04943042 | Swedish Orphan Biovitrum | — |
| Recruiting | A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia NCT05214391 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Completed | A Study of Zanubrutinib in Patients With ITP NCT05279872 | Peking University People's Hospital | Phase 2 |
| Unknown | Herombopag + rhTPO in Severe Immune Thrombocytopenia NCT05328804 | Yin Jie | Phase 3 |
| Unknown | A Study of Orelabrutinib in Patients With ITP NCT05124028 | Peking University People's Hospital | Phase 1 / Phase 2 |
| Recruiting | ITP Registry and Accompanying Biospecimen Collection NCT05152238 | Jena University Hospital | — |
| Withdrawn | SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies NCT05393999 | Imperial College Healthcare NHS Trust | Phase 2 |
| Unknown | Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia NCT05116423 | Peking University People's Hospital | — |
| Unknown | Atorvastatin in Management of Newly Diagnosed ITP NCT03692754 | Shandong University | Phase 2 / Phase 3 |
| Withdrawn | Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of NCT05046327 | Sobi, Inc. | Phase 3 |
| Unknown | Post IVIG Medication in Children With Immune Thrombocytopenia NCT04741139 | Baylor College of Medicine | Phase 1 |
| Recruiting | Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies NCT04993885 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Unknown | A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP NCT05020288 | Shandong University | Phase 2 |
| Unknown | The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopeni NCT05281068 | Peking University People's Hospital | Phase 2 |
| Active Not Recruiting | A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus NCT05023915 | Shandong University | Phase 2 |
| Unknown | The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopen NCT05353673 | Peking University People's Hospital | Phase 2 |
| Unknown | The Combination of Prednisone and Recombinant Human Thrombopoietin for Treatment of Immune Thrombocytopenia in NCT05333744 | Peking University People's Hospital | Phase 2 |
| Recruiting | Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune C NCT04800458 | University Hospital, Bordeaux | N/A |
| Terminated | Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP NCT04904276 | Rigel Pharmaceuticals | — |
| Completed | Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia NCT04737850 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Completed | Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag NCT04638829 | Sobi, Inc. | Phase 4 |
| Completed | Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 M NCT04516967 | Sobi, Inc. | Phase 3 |
| Unknown | The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytop NCT04747080 | Peking University People's Hospital | Phase 2 |
| Active Not Recruiting | Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia ( NCT04562766 | Principia Biopharma, a Sanofi Company | Phase 3 |
| Unknown | A Study of ATRA in the Treatment of ITP NCT04618328 | Peking University People's Hospital | Phase 2 |
| Unknown | Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia NCT04588194 | David Gomez Almaguer | Phase 2 |
| Unknown | Connection Between Vitamin D Level and the Efficacy of Dexamethasone in Immune Thrombocytopenia NCT04320225 | Shandong University | — |
| Unknown | A Multicenter Randomized Study of Vitamin D Combined With HD-DXM Versus HD-DXM for the Treatment of ITP NCT04094805 | Shandong University | Phase 4 |
| Unknown | Fixed Low-dose Eltrombopag and rhTPO for Immune Thrombocytopenia (FLOWER) NCT04518878 | Peking University People's Hospital | Phase 1 |
| Unknown | Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19) NCT04516837 | Peking University People's Hospital | Phase 2 |
| Unknown | The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopen NCT04481282 | Peking University People's Hospital | Phase 2 |
| Withdrawn | A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP NCT04039477 | Kezar Life Sciences, Inc. | Phase 2 |
| Unknown | Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura NCT04311593 | Assiut University | — |
| Unknown | Phase II Trial of Romiplostim With Danazol in Patients With Eltrombopag-resistant Immune Thrombocytopenia NCT04289207 | Seoul National University Hospital | Phase 2 |
| Completed | The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia NCT04217148 | Peking University People's Hospital | Phase 2 |
| Unknown | Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura NCT03172676 | Assiut University | Phase 4 |
| Unknown | Eltrombopag in Chronic ITP NCT04102033 | Assiut University | Phase 4 |
| Completed | Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) NCT04056195 | Oscotec Inc. | Phase 2 |
| Withdrawn | Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia NCT03965624 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopeni NCT05566990 | SK Plasma Co., Ltd. | Phase 3 |
| Unknown | Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP NCT03998982 | Shandong University | Phase 4 |
| Recruiting | Observatory of Immunological Thrombopenic Purpura in the Brest Region NCT06556888 | University Hospital, Brest | — |
| Recruiting | Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune NCT05931718 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | — |
| Completed | Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children NCT03939637 | Baylor College of Medicine | Phase 3 |
| Unknown | The Combination of High-dose Dexamethasone and Acetylcysteine as the Treatment of Newly-diagnosed ITP NCT04368598 | Peking University People's Hospital | Phase 2 |
| Completed | Association of Platelet Parameters With Bleeding Severity in Children With ITP NCT03810352 | Boston Children's Hospital | — |
| Recruiting | Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia NCT04005638 | University Hospital, Bordeaux | — |
| Completed | Risk Factors for Thrombosis in Immune Thrombocytopenia NCT03820960 | University Hospital, Toulouse | — |
| Unknown | Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP NCT03252457 | Shandong University | Phase 3 |
| Completed | A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics NCT03603132 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic Pur NCT03830749 | Humanity & Health Medical Group Limited | Phase 2 |
| Unknown | Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia NCT03492515 | Shandong University | Phase 3 |
| Completed | Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS) NCT03469661 | Fundacion CRIS de Investigación para Vencer el Cáncer | — |
| Completed | A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) NCT03395210 | Principia Biopharma, a Sanofi Company | Phase 2 |
| Unknown | The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immu NCT03460808 | Peking University People's Hospital | Phase 1 / Phase 2 |
| Completed | Severe Immune Cytopenia Registry Www.Sic-reg.Org NCT03576742 | Medical University of Graz | — |
| Unknown | Rituximab Combining Bortezomib Versus Rituximab in Management of ITP NCT03443570 | Shandong University | Phase 3 |
| Completed | The Serum Lipid Profiles in ITP: a Retrospective Study NCT05095896 | Ming Hou | — |
| Unknown | The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP NCT03377439 | Shandong University | — |
| Active Not Recruiting | The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia NCT03201848 | Qidong Gaitianli Medicines Co., Ltd | Phase 4 |
| Completed | Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Myco NCT03156452 | University Hospitals Bristol and Weston NHS Foundation Trust | Phase 3 |
| Unknown | The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocyt NCT03304288 | Peking University People's Hospital | Phase 2 |
| Completed | Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia NCT03229746 | Assiut University | Phase 4 |
| Unknown | Comparison Between Methyl Prednisolone and Intravenous Dexamethazone in Severe Immune Thrombocytopenic Purpra NCT03183284 | Assiut University | — |
| Unknown | H. Pylori Eradication for Moderate ITP NCT03177629 | Seoul National University Hospital | Phase 3 |
| Unknown | Evaluation of HRQoL in Adult With Immune Thrombocytopenia in China NCT03324087 | Shandong University | — |
| Completed | Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immu NCT03154385 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP) NCT03013114 | Shandong University | Phase 2 |
| Unknown | Clinical Trial of Gut Microbiota in the Management of Immune Thrombocytopenia NCT03033199 | Shandong University | Phase 2 |
| Withdrawn | Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytope NCT02649504 | Weill Medical College of Cornell University | Phase 3 |
| Unknown | RP% Measurement by FCM as a Diagnostic Test for ITP NCT02967328 | Shandong University | — |
| Completed | This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP) NCT02859909 | Biotest | Phase 3 |
| Unknown | Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocyto NCT03520049 | Unity Health Toronto | Phase 3 |
| Completed | A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia ( NCT03164915 | SK Plasma Co., Ltd. | Phase 3 |
| Unknown | DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients NCT02834468 | Shandong University | Phase 3 |
| Unknown | Treatment of ITP With Rituximab and / or Accutane NCT02757196 | Peking University People's Hospital | Phase 2 |
| Completed | Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytope NCT02298075 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Immunomodulation With Romiplostim in Young Adults With ITP NCT02760251 | University Hospital, Basel, Switzerland | Phase 4 |
| Unknown | Thrombocytopenia in Gestational Period NCT02751593 | Peking University People's Hospital | Phase 2 / Phase 3 |
| Withdrawn | Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP) NCT02642380 | Shandong University | Phase 4 |
| Terminated | PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP NCT02566603 | Protalex, Inc. | Phase 1 / Phase 2 |
| Completed | Caffeic Acid Combining High-dose Dexamethasone in Management of ITP NCT02556814 | Shandong University | Phase 4 |
| Terminated | PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP NCT02401061 | Protalex, Inc. | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) NCT02868099 | Kyowa Kirin China Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia NCT01568333 | Shandong University | Phase 2 |
| Unknown | Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia NCT02834286 | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 |
| Completed | A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy NCT02391272 | Shandong University | Phase 3 |
| Unknown | An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP NCT02338414 | Samsung Medical Center | Phase 2 |
| Completed | Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP) NCT02279173 | Amgen | Phase 3 |
| Unknown | Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP) NCT02821572 | Centre Hospitalier Universitaire Dijon | — |
| Unknown | Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy NCT02270801 | Shandong University | Phase 3 |
| Withdrawn | A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosp NCT02203422 | Shandong University | Phase 3 |
| Completed | An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia NCT02063789 | Green Cross Corporation | Phase 3 |
| Completed | An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP) NCT02153060 | Shandong University | Phase 2 |
| Withdrawn | A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resi NCT02137681 | Shandong University | Phase 3 |
| Completed | An Investigation of rhTPO With Different Frequencies in the Management of ITP NCT02139501 | Shandong University | Phase 3 |
| Unknown | Immune Thrombocytopenia in Pregnancy NCT02892630 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Throm NCT01933035 | Beth Israel Medical Center | — |
| Withdrawn | High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagno NCT01976195 | Shandong University | Phase 2 |
| Completed | ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP NCT01971684 | Boston Children's Hospital | — |
| Recruiting | French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia NCT02877706 | University Hospital, Toulouse | — |
| Unknown | Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia NCT01763658 | Ain Shams University | Phase 2 / Phase 3 |
| Withdrawn | Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag Trea NCT01864512 | Shandong University | — |
| Completed | Safety and Efficacy of Eltrombopag at Escalated Doses NCT01880047 | Weill Medical College of Cornell University | Phase 2 |
| Withdrawn | The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia NCT01869049 | Shandong University | — |
| Completed | Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP) NCT02287649 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Caffeic Acid Tablets as a Second-line Therapy for ITP NCT02351622 | Shandong University | Phase 3 |
| Completed | Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics NCT01727999 | Stanford University | — |
| Completed | Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With C NCT01438840 | Eisai Inc. | Phase 3 |
| Completed | Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety NCT01618734 | Henri Mondor University Hospital | — |
| Completed | A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplo NCT01974232 | Weill Medical College of Cornell University | — |
| Completed | Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients NCT01444417 | Amgen | Phase 3 |
| Terminated | End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia NCT01386723 | Weill Medical College of Cornell University | — |
| Unknown | Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP NCT01805648 | Peking Union Medical College | Phase 3 |
| Completed | Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia NCT01549184 | Henri Mondor University Hospital | — |
| Recruiting | OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia NCT05937828 | University Hospital, Bordeaux | — |
| Terminated | An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP) NCT01129024 | Shionogi | Phase 2 |
| Completed | The Study of Different Dose Rituximab in the Treatment of ITP NCT03258866 | Shandong University | Phase 4 |
| Completed | Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) NCT00902018 | Weill Medical College of Cornell University | Phase 2 |